A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

David McMullin,1 David Clark,1 Bill Cavanagh,1 Paul Karpecki,2 Todd C Brady1 1Aldeyra Therapeutics, Inc, Lexington, MA, USA; 2Kentucky Eye Institute, Lexington, KY, USACorrespondence: Todd C BradyAldeyra Therapeutics, Inc, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USATel +1 781 761-4904E...

Full description

Saved in:
Bibliographic Details
Main Authors: McMullin D, Clark D, Cavanagh B, Karpecki P, Brady TC
Format: article
Language:EN
Published: Dove Medical Press 2021
Subjects:
Online Access:https://doaj.org/article/8ed6c8cfce4d4c78970537ad6781fa01
Tags: Add Tag
No Tags, Be the first to tag this record!